Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease.

abstract：:Various pathways lead to the development of venous thrombosis. Risk factors are common and can be genetic or acquired. Since the identification of factor V Leiden and prothrombin 20210 G-->A, the field of genetic epidemiology has developed rapidly and many new genetic variants have been described in the past decade. H...

journal_title：Seminars in hematology

authors： Bezemer ID,Rosendaal FR

更新日期：2007-04-01 00:00:00

abstract：:Virtually all human cells are endowed with the capacity to commit suicide using an evolutionarily conserved mechanism that involves activation of caspase-family cell death proteases. Caspase activation culminates in a cell death process known as "apoptosis." The activation of these intracellular proteases is carefully...

journal_title：Seminars in hematology

authors： Reed CJ

更新日期：2000-10-01 00:00:00

abstract：:Since warfarin remains the predominate drug administered for long-term anticoagulation, optimizing therapy for maximum antithrombotic effect with minimal bleeding risk continues to challenge clinicians. Genetic differences exist that affect an individual's response to warfarin. The clinician can use genetic informatio...

journal_title：Seminars in hematology

authors： Chai SJ,Macik BG

更新日期：2002-07-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are clonal disorders characterized by ineffective hematopoiesis and subsequent frequent development of acute myeloid leukemia (AML). In children and adolescents, MDS are uncommon disorders, accounting for less than 5% of hematopoietic malignancy, with great heterogeneity in presentation...

journal_title：Seminars in hematology

authors： Niemeyer CM,Baumann I

更新日期：2008-01-01 00:00:00

abstract：:The standard treatment of multiple myeloma is systemic chemotherapy. Despite 30 years of drug development in myeloma, there are no new drug regimens significantly superior to melphalan and prednisone. In addition, phase II studies of new drugs in myeloma have been disappointing, with low response rates and no prolonga...

journal_title：Seminars in hematology

authors： Kraut EH,Ju R,Muller M

更新日期：1998-07-01 00:00:00

abstract：:The successful clinical development of thalidomide, bortezomib, and lenalidomide not only transformed the therapeutic management of multiple myeloma (MM) but also catalyzed a renewed interest in the development of additional classes of novel agents for this disease. This review focuses on a series of new therapeutics ...

journal_title：Seminars in hematology

authors： Mitsiades CS,Hideshima T,Chauhan D,McMillin DW,Klippel S,Laubach JP,Munshi NC,Anderson KC,Richardson PG

更新日期：2009-04-01 00:00:00

abstract：:Management of patients with beta-thalassemia is based on adequate, safe blood transfusions (free of transfusion-transmitted diseases) and prevention of iron overload. Iron overload causes multiple endocrinopathies, contributes to osteoporosis, and is the cause of cardiac disease. Cardiac disease, secondary to iron dam...

journal_title：Seminars in hematology

authors： Wonke B

更新日期：2001-10-01 00:00:00

abstract：:Anemia of chronic disease (ACD) or inflammation may be secondary to infections, autoimmune disorders, chronic renal failure, or malignancies. It is characterized by an immune activation with an increase in inflammatory cytokines and resultant increase in hepcidin levels. In addition, inappropriate erythropoietin level...

journal_title：Seminars in hematology

authors： Gangat N,Wolanskyj AP

更新日期：2013-07-01 00:00:00

abstract：:The molecular causes of hereditary spherocytosis (HS) have been unraveled in the past decade. No frequent defect is found, and nearly every family has a unique mutation. In dominant HS, nonsense and frameshift mutations of ankyrin, band 3, and beta-spectrin predominate. Recessive HS is most often due to compound heter...

journal_title：Seminars in hematology

authors： Eber S,Lux SE

更新日期：2004-04-01 00:00:00

abstract：:Imatinib mesylate (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ; Glivec, Novartis Pharma AG, Basel, Switzerland), a signal transduction inhibitor with preferential effects against the tyrosine kinase activity of the protein product of the ABL proto-oncogene, induced hematologic responses in >or=90% of pati...

journal_title：Seminars in hematology

authors： Hoelzer D,Gökbuget N,Ottmann OG

更新日期：2002-10-01 00:00:00

abstract：:Imatinib (Gleevec) (formerly STI571) is an orally bioavailable rationally developed inhibitor of the tyrosine kinases Bcr-Abl, Kit, and platelet-derived growth factor receptor (PDGFR). In 4 years of clinical development, more than 12,000 patients have been treated in the clinical development program. Imatinib was firs...

journal_title：Seminars in hematology

authors： Capdeville R,Silberman S

更新日期：2003-04-01 00:00:00

abstract：:Although often overlooked, the life of the patient with severe hemophilia is characterized by both intermittent and chronic pain. Bleeds into joints and muscles cause extensive pressure on sensory nerves and, following recurrent bleeds, joint destruction, and synovial reaction is accompanied by constant pains that are...

journal_title：Seminars in hematology

authors： Ingerslev J,Hvid I

更新日期：2006-01-01 00:00:00

abstract：:The inhibitor titer is the most important clinical measurement in inhibitor patients, and the Nijmegen method is preferable to the original and well-established Bethesda assay for this purpose; however, both methods have high inter-laboratory variability. Monitoring inhibitor patients after treatment with bypassing ag...

journal_title：Seminars in hematology

authors： Barrowcliffe TW

更新日期：2008-04-01 00:00:00

abstract：:A retrospective study was conducted to determine treatment patterns for idiopathic thrombocytopenia purpura (ITP) across the US and to determine the cost of its treatment with high-dose intravenous immunoglobulin (IVIg) and anti-D therapy. Information on the incidence, treatment patterns, hospital care, and costs for ...

journal_title：Seminars in hematology

authors： Simpson KN,Coughlin CM,Eron J,Bussel JB

更新日期：1998-01-01 00:00:00

abstract：:While the prevalence of iron deficiency has remained relatively constant, there has been continuing refinement in its laboratory recognition, especially with the recent introduction of serum ferritin and FEP measurements. It is helpful to classify iron deficiency into three stages. Storage iron depletion is identified...

journal_title：Seminars in hematology

authors： Cook JD

更新日期：1982-01-01 00:00:00

abstract：:The present review will briefly summarize the interplay between coagulation and inflammation, highlighting possible effects of direct inhibition of factor Xa and thrombin beyond anticoagulation. Additionally, the rationale for the use of the new direct oral anticoagulants (DOACs) for indications such as cancer-associa...

journal_title：Seminars in hematology

authors： Alberio L

更新日期：2014-04-01 00:00:00

abstract：:Peripheral suppression of autoreactive T cells by specialized T-cell populations is one of several mechanisms ensuring self-tolerance within the adaptive immune system. Thymus-derived CD4+CD25+ T cells expressing the transcriptional repressor FOXP3 mediate such immunoregulatory functions and are pivotal for the preven...

journal_title：Seminars in hematology

authors： Hoffmann P,Edinger M

更新日期：2006-01-01 00:00:00

abstract：:The purpose of this study was to assess the efficacy and side effect profile of the repeated use of anti-D for the treatment of pediatric immune thrombocytopenia (ITP) in a large pediatric hematology center. We performed a retrospective analysis of patient records for children (aged 4 months-18 years) treated for ITP ...

journal_title：Seminars in hematology

authors： Yacobovich J,Abu-Ahmed S,Steinberg-Shemer O,Goldberg T,Cohen M,Tamary H

更新日期：2016-04-01 00:00:00

abstract：:The results of the Y-chromosome in situ hybridization experiments, the MRA assessment, and the long-term production of CFU-GM in vitro indicate that our protocol to sort low density WGA+, 15/1.1-, Rh123 dull cells enriches about 200-fold for PHSC. Assays for spleen colony formation (CFU-S) and radioprotection (30-day ...

journal_title：Seminars in hematology

authors： Visser JW,de Vries P,Hogeweg-Platenburg MG,Bayer J,Schoeters G,van den Heuvel R,Mulder DH

更新日期：1991-04-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is probably the best understood human malignancy at the molecular level, but among the hardest to explain to patients concerning appropriate treatment options. At present, we do not know the long-term outcome of promising new therapies such as the tyrosine kinase inhibitor imatinib mesyl...

journal_title：Seminars in hematology

authors： Appelbaum FR

更新日期：2001-07-01 00:00:00

abstract：:The risk of postoperative venous thromboembolism (VTE) is dependent on the type of surgical procedure and specific characteristics of the patient. Patients with intrinsic factors placing them at higher risk of VTE remain at high risk, even if the procedural risk is low. The identification of factors such as age, obesi...

journal_title：Seminars in hematology

authors： Samama MM

更新日期：2000-07-01 00:00:00

abstract：:Autologous hematopoietic stem cell transplantation (HSCT) has a long tradition in Europe. Initially developed as a tool to restore rapid remission or chronic phase in patients with advanced leukemia without a sibling donor, it evolved over the last three decades to be used as a standard tool in patients with malignanc...

journal_title：Seminars in hematology

authors： Gratwohl A

更新日期：2007-10-01 00:00:00

abstract：:Primary immune thrombocytopenic purpura (ITP) remains a diagnosis of exclusion both from nonimmune causes of thrombocytopenia and immune thrombocytopenia that develops in the context of other disorders (secondary immune thrombocytopenia). The pathobiology, natural history, and response to therapy of the diverse causes...

journal_title：Seminars in hematology

authors： Cines DB,Liebman H,Stasi R

更新日期：2009-01-01 00:00:00

abstract：:The central hypothesis of our laboratory research program in large granular lymphocyte (LGL) leukemia is that leukemic LGL represent antigen-driven cytotoxic T lymphocytes (CTL) with characteristics of dysregulated apoptosis. The clinical features of LGL leukemia highlight the association of autoimmune diseases such a...

journal_title：Seminars in hematology

authors： Epling-Burnette PK,Loughran TP Jr

更新日期：2003-07-01 00:00:00

abstract：:Mantle-cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells characterized by a nodular or diffuse proliferation of atypical lymphoid cells with a monoclonal B-cell phenotype and coexpression of CD5. Two cytologic variants have been identified, typical and blasti...

journal_title：Seminars in hematology

authors： Campo E,Raffeld M,Jaffe ES

更新日期：1999-04-01 00:00:00

abstract：:Familial thrombosis has long been considered as an autosomal dominant trait, caused by a dominant gene defect with a reduced penetrance for the disease. Recently, this view has changed and today familial thrombophilia is considered as a complex genetic disorder caused by the segregation of two or more gene defects (kn...

journal_title：Seminars in hematology

authors： Koeleman BP,Reitsma PH,Bertina RM

更新日期：1997-07-01 00:00:00

abstract：:Trauma is rapidly replacing stroke and cardiovascular disease as a leading cause of death in Western countries such as the United States, and almost a third (30%) of trauma deaths are due to blood loss. Although the new intervention strategies that have been developed and adopted by emergency care staff have reduced t...

journal_title：Seminars in hematology

authors： Hoyt DB

更新日期：2004-01-01 00:00:00

abstract：:Psoralens plus ultraviolet A (UVA) light inactivate viruses and bacteria as well as leukocytes. A system employing the synthetic psoralen compound amotosalen hydrochloride (S-59), in combination with UVA light, is being developed to decontaminate platelet concentrates and plasma in a blood-bank setting. S-59 is a hete...

journal_title：Seminars in hematology

authors： Wollowitz S

更新日期：2001-10-01 00:00:00

abstract：:Both thalidomide and intermittent high-dose dexamethasone are agents with established activity against multiple myeloma. We summarized our experience with thalidomide alone, and then in combination with dexamethasone, for groups of patients with myeloma resistant or relapsing despite standard treatments. Criteria of r...

journal_title：Seminars in hematology

authors： Alexanian R,Weber D,Anagnostopoulos A,Delasalle K,Wang M,Rankin K

更新日期：2003-10-01 00:00:00

abstract：:A multicenter clinical trial of the thrombin inhibitor argatroban (Novastan; Texas Biotechnology, Houston, TX; Smith-Kline Beecham Pharmaceuticals, Philadelphia, PA) was recently conducted in patients with heparin-induced thrombocytopenia (HIT) and HIT that had progressed to thrombosis (HITTS). In patients defined by ...

journal_title：Seminars in hematology

authors： Walenga JM,Jeske WP,Wood JJ,Ahmad S,Lewis BE,Bakhos M

更新日期：1999-01-01 00:00:00